|Articles|October 19, 2022
On the way towards personalized medicine: Gene therapy AAV characterization by CE and LC-MS
Author(s)Sciex
As more gene therapy applications make inroads into research and clinical practice, the development and safe manufacturing of the therapeutic products involved have demanded more from associated analytical technologies. One of the most widely used gene-therapy vectors is AAV, and key technologies for the characterization of AAVs include CE and LC-MS.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Charles River Incubator Cohort to Accelerate CGT Development
2
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
3
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
4
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
5
